The effect of sibutramine therapy on occurrence of depression symptoms among obese patients

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 18, Issue 8, 2008, Pages

  Slovacek, L ^a   Pavlik, V ^b   Slovackova, B ^c  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; ANTIDEPRESSANT AGENT; CYCLOBUTANE DERIVATIVE; SIBUTRAMINE;

BODY MASS; DEPRESSION; HUMAN; LETTER; LONGITUDINAL STUDY; MORBID OBESITY; OBESITY; PSYCHOLOGICAL ASPECT; WEIGHT REDUCTION;

ANTIDEPRESSIVE AGENTS; APPETITE DEPRESSANTS; BODY MASS INDEX; CYCLOBUTANES; DEPRESSION; HUMANS; LONGITUDINAL STUDIES; OBESITY; OBESITY, MORBID; WEIGHT LOSS;

EID: 51249104658     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2008.04.002     Document Type: Letter

References (6)

1. Nisoli E., and Carruba M.O. A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf 26 14 (2003) 1024-1048
2. Wirth A. Weight loss via drug therapy. Internist (Berl) 44 3 (2003) 359-362 363-6
3. Payer J., Hainer V., Ondrejka P., and Kajtor Z. Sibutramin in obesity treatment (multicenter, open, prospective 12-month-long study). Vnitr Lek 50 11 (2004) 825-829
4. Luque C.A., and Rey J.A. The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol 440 2-3 (2002) 119-128
5. Kiortsis D.N., Tsouli S., Filippatos T.D., Konitsiotis S., and Elisaf M.S. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. Nutr Metab Cardiovasc Dis 18 3 (2008) 207-210
6. Mannuci E., Dicembrini I., Rotella F., and Rotela C.H. Orlistat and sibutramine beyond weight loss. Nutr Metab Cardiovasc Dis 18 5 (2008) 342-348